Better Health for All

Astria Therapeutics' core business is entirely devoted to developing life-changing therapies for allergic and immunologic diseases, with 100% of its R&D focused on improving health outcomes. Its lead product candidate, navenibart, is being developed as a preventative treatment for hereditary angioedema (HAE) attacks.

Clinical trials for navenibart demonstrated robust attack rate reductions, ranging from 84% to 92% mean/median across cohorts, and showed clinically meaningful improvements in patient-reported quality of life. All 29 patients in the ALPHA-STAR trial chose to enroll in a long-term open-label trial. The drug was generally well-tolerated, with no serious treatment-emergent adverse events or discontinuations due to adverse events, and only four non-severe, quickly resolved treatment-related adverse events reported. The company includes a section on "Forward-Looking Statements" in its press releases, outlining various risks and uncertainties. , Clinical trials are designed with input from patients, caregivers, and physicians. As the company does not currently manufacture or distribute products, it generates no revenue from potentially harmful activities. Information regarding price accessibility, vulnerable reach, health externalities, health equity programs, healthcare workforce support, healthcare data responsibility, global health crisis response, mental health initiatives, pharma patent flexibility, nutrition and food safety, healthcare education, or addiction mitigation is not available for Astria Therapeutics, Inc.

Fair Pay & Worker Respect

No quantitative data relevant to the specified Fair Pay & Worker Respect KPIs was found in the provided articles.

The articles mention Astria Therapeutics' recognition as a top workplace and positive employee feedback regarding company culture, respect, care, and responsiveness, but they do not provide specific metrics such as living wage coverage, CEO-median pay ratio, collective bargaining share, safety incident rates, pay equity ratios, worker engagement scores, turnover rates, labor violation incidents, insecure contract share, or health insurance coverage.

Honest & Fair Business

Astria Therapeutics has a compliance reporting hotline that allows anonymous reporting of violations.

Reports are encrypted and delivered to the Chair of the Board, Audit Committee Chair, and Head of Legal. The Audit Committee handles accounting, internal controls, and auditing matters, with other concerns handled by the Board Chair and Head of Legal. A secure web form and secure hotline are available.

Kind to Animals

No specific, concrete data points were found in the provided articles to assess Astria Therapeutics, Inc. against any of the 'Kind to Animals' KPIs. While one article mentioned the company's involvement in animal testing, it did not provide details on the volume of animals used, the company's animal testing policy, or any other relevant metrics required by the rubric.

Information regarding the FDA's broader initiatives on phasing out animal testing was present, but this does not constitute evidence of ATXS.US's specific practices, policies, or investments.

No War, No Weapons

Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases. The company's core business does not involve arms manufacturing, military contracts, or conflict facilitation.

The provided articles explicitly state that there is no involvement in controversial weapons and no quantitative data for any metrics related to arms sales, defense contracts, dual-use technology, or conflict-related activities. Therefore, all relevant KPIs are scored as N/A, indicating that these activities are not applicable to the company's core operations.

Planet-Friendly Business

No specific quantitative data, certifications, or violations related to environmental performance for Astria Therapeutics, Inc. were provided in the articles.

The articles only indicate the potential availability of various reports online, but do not contain any specific data from these reports to assess performance against the Planet-Friendly Business KPIs.

Safe & Smart Tech

Astria Therapeutics reported no material cybersecurity incidents that have affected or are likely to affect its business, operations, or financial condition as of March 4, 2024.

The company has processes in place for assessing, identifying, and managing cybersecurity risks, including regular exercises and tests. Employees are trained to recognize and report potential incidents, fostering a culture of cybersecurity awareness. No incidents of unauthorized data use were reported. The company's privacy policy outlines data subject rights, including access, rectification, and erasure, and mentions collecting only necessary data. Astria Therapeutics states compliance with GDPR, CCPA, and other relevant privacy laws.

Zero Waste & Sustainable Products

The provided articles, including ESG risk reports from Sustainalytics and a corporate responsibility report from Astria Therapeutics, Inc., explicitly state that they do not contain any specific quantitative data or concrete facts related to waste management, product sustainability, or circular economy practices. There is no information available on waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certifications, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education programs.

The company description notes that Astria Therapeutics does not currently manufacture or distribute products, focusing instead on research and development.